Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/17155
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorFeng, Xiaojun; Soldevila Verdeguer, Carla; Jafari, Samineh; Memariani, Zahra; Tewari, Devesh; Annunziata, Giuseppe; Barrea, Luigi; Hassan, Sherif T. S.; Smejkal, Karel; Malanik, Milan; Sychrova, Alice; Barreca, Davide; Ziberna, Lovro; Mahomoodally, Mohamad Fawzi; Zengin, Gokhan; Xu, Suowen; Nabavi, Seyed Mohammad; Shen, Ai-Zong
Document typereview article
CitationFeng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-51.
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.